Advertisement

Topics

Latest "Jagged Peak Announces Financial Results Second Quarter 2015" News Stories

12:50 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "Jagged Peak Announces Financial Results Second Quarter 2015" found in our extensive news archives from over 250 global news sources.

More Information about Jagged Peak Announces Financial Results Second Quarter 2015 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Jagged Peak Announces Financial Results Second Quarter 2015 for you to read. Along with our medical data and news we also list Jagged Peak Announces Financial Results Second Quarter 2015 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Jagged Peak Announces Financial Results Second Quarter 2015 Companies for you to search.

Showing "Jagged Peak Announces Financial Results Second Quarter 2015" News Articles 1–25 of 32,000+

Saturday 20th October 2018

ABT Molecular Imaging Inc Medical Equipment Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryABT Molecular Imaging Inc ABT is a medical imaging company engaged in the development of biomarker generator systems and related accessories. Its technology platform BG75, a biomarker generator produces unit doses of molecular imaging drugs for positron emission tomography PET at the point of use, eliminating the need for chemistry and physics expertise. ABT s generator includes a selfshiel...


2018 Global Medical Device Market: Sales Segment Forecasts and Strategic Assessments of Leading Suppliers [Report Updated: 01011970] Prices from USD $7500

Complete report $14,500.nbsp; Individual company assessments $2,450.nbsp; The report is available by company, section, market segment, and can be customtailored to your specific information needs and budget.This unique study is designed to provide diagnostic imaging industry executives with strategically significant competitor information, analysis and insight crucial to the development and implem...

Obalon Therapeutics Inc OBLN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryObalon Therapeutics Inc Obalon Therapeutics is a manufacturer of medical devices and equipment. The company offers development and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It also researches, designs, produces, and sells medical gastric balloon for weight loss therapy. Obalon Therapeutics' Obalon Balloon System is a swallowable intrag...


SonarMed Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250

SummarySonarMed Inc SonarMed is a medical device company that develops endotrachael systems used for the inhalation and ventilation assistance patients. The company offers products such as artificial respiratory, endotrachael tubes, biomedical acoustics, SonarMed Airwave, medical devices, disposable medical products, LED vital signs and adjunctive devices, among others. It also offers adapters, mo...

Folia Biotech Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryFolia Biotech Inc Folia Biotech is a biopharmaceutical company that research and develops vaccines against infectious diseases. The company uses its immunotherapeutic platform to discover and develop new treatments for cancer and immune diseases. Its immunotherapeutic platform comprises a novel tolllike receptor agonist nanoparticle. Folia Biotech develops novel vaccines based on its immuno...

Linde AG LIN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummaryLinde AG Linde is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. It offers a wide range of compressed, liquefied gases and chemicals. It also offers engineering services to petrochemical and chemical industries. The company offers medical gases and services to ...

Purdue University Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryPurdue University Purdue is an academic and research institution that offers undergraduate, post graduate, honors and research programs. The institution provides offcampus academic programs such as distance learning, zip trips, youth programs and opportunities to study abroad. It offers undergraduate courses in the fields of accounting, agriculture, education, engineering, animation, anthro...

GenVec Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryGenVec Inc GenVec focuses on the research and development of genebased medicine. It develops therapeutics and vaccines using its proprietary adenovector gene delivery platform. The company's lead product, CGF166 is licensed to Novartis Institutes and is in Phase I/II for the treatment of hearing loss and balance disorders. Its therapeutics portfolio includes novel drugs for cancer, bleeding...

sanofiaventis US LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummarySanofiAventis US LLC Sanofi US, a subsidiary of Sanofi is a drug company that discovers, develops and distributes various therapeutic solutions. The company provides prescription products, vaccines and other products. Sanofi US's vaccines include ActHIB, Adacel, DAPTACEL, Decavac, Fluzone, Imogam, IPOL, Menactra, Menomune, TheraCys, Typhim Vi, YFVAX, and Pentacel among others. The company's...

Quark Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250

SummaryQuark Pharmaceuticals Inc Quark, a subsidiary of SBI Biotech Co Ltd, is a clinicalstage pharmaceutical company that strives to discover and develop RNAibased therapeutics. The company's pipeline product portfolio comprises QPI1002, for acute kidney injury and delayed graft function; QPI1007, for non arteritic anterior ischemic optic neuropathy; and PF655, for diabetic macular edema and ager...

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine Pfizer Inc.(NYSE:PFE) today announced detail...

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo p...

Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

– Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer – – Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations – – Clinically meaningful overall survival improvement in the ...

Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer

Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

Arbutus Biopharma Corp ABUS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryArbutus Biopharma Corp Arbutus Biopharma, formerly Tekmira Pharmaceuticals Corporation, is a biopharmaceutical company that focuses on the discovery, development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection. Its pipeline includes HBV candidates such as ARB1467 for HBsAg expression in patients chronically in...

Norgine BV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryNorgine BV Norgine is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, critical and supportive care. Norgine offers ...

IMV Inc IMV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24072018] Prices from USD $250

SummaryIMV Inc IMV formerly known as Immunovaccine Inc, is a clinicalstage immunooncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a vaccine adjuvant and delivery platform technology. Its immuno oncology pipeline products are intended for the treatment of ovarian, diffuse large B cell lymphoma DLBCL t...

Confluence Life Sciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryConfluence Life Sciences Inc Confluence is a medicines developing company that discovers medicine for treatment of cancer and autoimmune and inflammatory. The company designs and develops kinase inhibitors focusing on the enzymes that regulate the growth of enzymes for cancer, chronic inflammation and survival and metastasis. Its pipeline product portfolio comprises TAK1 cancer, CDD450 MK2 ...

TechnoPhage SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryTechnoPhage SA TechnoPhage is a biopharmaceutical company that offers contract research and development of new molecules. The company conducts its research and development of new products based on unique properties of bacteriophages. It also conducts contract research and development services for private and public institutions and pharmaceutical companies, among others. TechnoPhage also co...

CanFite BioPharma Ltd CANF Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryCanFite BioPharma Ltd CanFite is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company's pipeline products which are in phase II and III clinical development stage includes CF101, for rheumatoid arthritis and psoriasis; CF102, for hepatocellular carcinoma; and CF602, for erectile dysfunction....

UCB reports positive results from phase 2 study of rozanolixizumab in MG patients

UCB has announced positive results from a phase 2 study (MG0002; NCT03052751) with a novel, subcutaneous FcRn (neonatal Fc receptor) monoclonal antibody, rozanolixizumab, in patients with myasthenia gravis

Molecular Templates Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Molecular Templates Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Molecular Templates Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertak...

Hansen Medical, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Hansen Medical, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Hansen Medical, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ...

STAT Plus: Is ‘STING’ a new and promising cancer target? Don’t look at Merck’s study results for a definitive answer

Merck debuted a new immune-boosting drug Saturday. But the clinical results raise a question: is the company heeding a hard lesson learned from its biggest blunder?

University of Toronto Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummaryUniversity of Toronto UT is an educational and research service provider that offers undergraduate and postgraduate courses in various fields. The university offers courses in various fields such as applied science and engineering, architecture, landscape, design, arts and science, continuing studies, school of dentistry education, forestry education. It provides services such as arts, scie...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks